When was Aprecia Pharmaceuticals founded?

Aprecia Pharmaceuticals was founded in 2003 and raised its 1st funding round 3 years after it was founded.

Where is Aprecia Pharmaceuticals located?

Aprecia Pharmaceuticals is headquartered in Langhorne, United States.

Who is the current CEO of Aprecia Pharmaceuticals?

Don Wetherhold and Owen Murray s of Aprecia Pharmaceuticals.

How many employees does Aprecia Pharmaceuticals have?

As of Jun 30, 2026, the latest employee count at Aprecia Pharmaceuticals is 65.

Is Aprecia Pharmaceuticals an acquired company?

Aprecia Pharmaceuticals got acquired by undefined on Oct 01, 2011.

Is Aprecia Pharmaceuticals a funded company?

Aprecia Pharmaceuticals is a funded company, having raised a total of $176M across 11 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 2006.

When was the latest funding round of Aprecia Pharmaceuticals?

Aprecia Pharmaceuticals' latest funding was a $***** Venture Debt round on Jul 05, 2016, with participation from 1 investor.

Where does Aprecia Pharmaceuticals rank among its competitors?

Aprecia Pharmaceuticals ranks 17th amongst 1963 active competitors, of which 455 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Aprecia Pharmaceuticals?

Aprecia Pharmaceuticals' top competitors include Synthego, Antheia and Transcenta. Among them, Antheia secured the most recent funding round in January, 2026.

Aprecia Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

Company Details

Aprecia Pharmaceuticals develops and manufactures orodispersible tablets with a focus on high-dose medications using ZipDose Technology. ZipDose Technology utilizes its proprietary three-dimensional printing (3DP) platform. This process stitches together multiple layers of powdered medication using an aqueous fluid to produce a porous, water-soluble matrix that rapidly disintegrates with a sip of liquid. FDA has recently approved SPRITAM levetiracetam for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy. SPRITAM utilizes its proprietary ZipDose Technology platform to produce a porous formulation that rapidly disintegrates with a sip of liquid. It plans to introduce multiple new products utilizing ZipDose Technology, focusing first on the central nervous system therapeutic area.

Key Metrics

Founded Year

2003

Location

Langhorne, United States

Stage

Acquired

Total Funding

$176M in 11 rounds

Latest Funding Round

Venture Debt, Jul 05, 2016, $*****

Investors

Deerfield & 3 more

Ranked

17^th among 1963 active competitors

Employee Count

65 as on Jun 30, 2026

Similar Companies

Synthego & 2672 more

Exit Details

Acquired

View Aprecia Pharmaceuticals' full profile

Aprecia Pharmaceuticals is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Aprecia Pharmaceuticals Co CIN: 1299458 , United States, Active		$1 - $1M (As on Dec 10, 2013)	-	-
APRECIA PHARMACEUTICALS, LLC CIN: 611852066 , United States, Active	May 28, 2015	-	39 (As on Dec 31, 2024)	-
Aprecia Pharmaceuticals Company CIN: 200457538 , United States, Active	Dec 31, 1999	-	43 (As on Dec 31, 2017)	-
APRECIA PHARMACEUTICALS, LLC CIN: 32065437991 , United States, Active	Nov 15, 2017	-	-	-

Aprecia Pharmaceuticals got acquired by on Oct 01, 2011.

Click here to take a look at Aprecia Pharmaceuticals's acquisition in detail

Aprecia Pharmaceuticals has raised a total funding of $176M over 11 rounds. Its first funding round was on Mar 2006. Its latest funding round was a Venture Debt round on Jul 05, 2016 for $*****. 1 investor participated in its latest round. Aprecia Pharmaceuticals has 4 institutional investors.

Here is the list of recent funding rounds of Aprecia Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 05, 2016	2327846	Venture Debt	5217532	5394788	8929805	2061044
Jan 14, 2016	6928777	Series D	4357963	8289084	8958304	2131586
Aug 31, 2015	2412206	Series D	8552807	8855109	2622469	7535362

Access funding benchmarks and valuations. Sign up today!

View details of Aprecia Pharmaceuticals's funding rounds and investors

Aprecia Pharmaceuticals' employee count trend

Aprecia Pharmaceuticals has 65 employees as of Jun 26. Here is Aprecia Pharmaceuticals's employee count trend over the years:

Employee count trend for Aprecia Pharmaceuticals

Uncover Aprecia Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Aprecia Pharmaceuticals include Synthego, Antheia and Transcenta. Here is the list of Top 10 competitors of Aprecia Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, RA Capital Management & 30 others	71/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Sequoia Capital & 11 others	66/100
4th	Judges Scientific 2002, London (United Kingdom), Public	Acquisition and development of scientific instrument businesses	-	Origin Capital, Lloyds Banking Group	65/100
5th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Sino Biopharmaceutical, Orbimed & 18 others	65/100
6th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Fidelity Investments, Invus & 14 others	64/100
7th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
8th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
9th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$346M	Maverick Ventures, Polaris Partners & 16 others	62/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
17th	Aprecia Pharmaceuticals 2003, Langhorne (United States), Acquired	Develops & manufactures orodispersible formulations of highly prescribed high-dose medications using proprietary drug delivery systems.	$176M	Deerfield, Hercules Capital & 2 others	60/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Aprecia Pharmaceuticals's competitors? Click here to see the top ones

Aprecia Pharmaceuticals has made no investments or acquisitions yet.

Here is the latest report on Aprecia Pharmaceuticals's geography:

Free

US Fintech Quarter Funding Report

Edition: Quarter 1, 2026 (41 Pages)

View all reports related to Aprecia Pharmaceuticals

Media has covered Aprecia Pharmaceuticals for a total of 2 events in the last 1 year, 1 of them has been about company updates and 1 about partnerships.